AMRX Amneal Pharmaceuticals Inc

Price (delayed)

$5.52

Market cap

$1.69B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.48

Enterprise value

$4.35B

Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in ...

Highlights
AMRX's EPS is up by 44% year-on-year
The company's net income rose by 35% YoY
The company's gross profit rose by 4.6% YoY but it fell by 3% QoQ
Amneal Pharmaceuticals's equity has shrunk by 94% QoQ and by 93% YoY
AMRX's quick ratio is down by 19% from the previous quarter and by 18% YoY

Key stats

What are the main financial stats of AMRX
Market
Shares outstanding
307.01M
Market cap
$1.69B
Enterprise value
$4.35B
Valuations
Price to book (P/B)
85.54
Price to sales (P/S)
0.41
EV/EBIT
32.17
EV/EBITDA
11.92
EV/Sales
1.82
Earnings
Revenue
$2.39B
EBIT
$135.09M
EBITDA
$364.49M
Free cash flow
$298.78M
Per share
EPS
-$0.48
Free cash flow per share
$1.7
Book value per share
$0.06
Revenue per share
$13.59
TBVPS
$11.26
Balance sheet
Total assets
$3.47B
Total liabilities
$3.45B
Debt
$2.75B
Equity
$19.78M
Working capital
$531.27M
Liquidity
Debt to equity
139.05
Current ratio
1.63
Quick ratio
0.84
Net debt/EBITDA
7.27
Margins
EBITDA margin
15.2%
Gross margin
34.3%
Net margin
-3.5%
Operating margin
7.9%
Efficiency
Return on assets
-2.3%
Return on equity
-34.9%
Return on invested capital
3.4%
Return on capital employed
5.1%
Return on sales
5.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AMRX stock price

How has the Amneal Pharmaceuticals stock price performed over time
Intraday
-2.99%
1 week
-9.8%
1 month
3.95%
1 year
315.04%
YTD
-9.06%
QTD
-8.91%

Financial performance

How have Amneal Pharmaceuticals's revenue and profit performed over time
Revenue
$2.39B
Gross profit
$820.57M
Operating income
$189.88M
Net income
-$83.99M
Gross margin
34.3%
Net margin
-3.5%
AMRX's net margin is up by 41% year-on-year
The company's net income rose by 35% YoY
The operating margin has declined by 17% since the previous quarter
The company's operating income fell by 17% QoQ

Growth

What is Amneal Pharmaceuticals's growth rate over time

Valuation

What is Amneal Pharmaceuticals stock price valuation
P/E
N/A
P/B
85.54
P/S
0.41
EV/EBIT
32.17
EV/EBITDA
11.92
EV/Sales
1.82
AMRX's EPS is up by 44% year-on-year
Amneal Pharmaceuticals's equity has shrunk by 94% QoQ and by 93% YoY
The price to sales (P/S) is 37% higher than the 5-year quarterly average of 0.3 and 37% higher than the last 4 quarters average of 0.3
AMRX's revenue is up by 8% year-on-year

Efficiency

How efficient is Amneal Pharmaceuticals business performance
AMRX's ROS is down by 35% since the previous quarter
AMRX's ROIC is down by 33% from the previous quarter
The company's return on assets rose by 30% YoY
Amneal Pharmaceuticals's return on equity has increased by 15% YoY

Dividends

What is AMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMRX.

Financial health

How did Amneal Pharmaceuticals financials performed over time
AMRX's quick ratio is down by 19% from the previous quarter and by 18% YoY
The company's current ratio fell by 15% QoQ and by 13% YoY
Amneal Pharmaceuticals's equity has shrunk by 94% QoQ and by 93% YoY
AMRX's debt is down by 3.3% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.